Publications by authors named "C Sault"
Objective: The first trimester combined risk of trisomy 21 is obtained by multiplying the risk related to maternal age by the likelihood ratios of nuchal translucency, free beta-human chorionic gonadotrophin (β-hCG) and placenta associated plasma protein-A. Beyond five multiples of the median (MoM) of β-hCG, the risk of trisomy 21 is truncated. The objective of the present study was to evaluate the evolution of the first trimester combined risk of trisomy 21 in individuals with first-trimester free-β-hCG levels between 5 and 10 MoM.
View Article and Find Full Text PDFIntroduction: We aimed to identify the most relevant cost-effectiveness threshold of first-trimester Down syndrome (DS) maternal serum screening (T21T1) for the use of cell-free DNA (cfDNA) as a second-tier test in the French context.
Method: A cost-effectiveness analysis was performed on 108,121 singleton pregnancies using a simulation model. The threshold of T21T1 screening was ranged from 1/51 to 1/1,000 in steps of 1/50.
Article Synopsis
- The study highlights the involvement of angiogenic factors (like sFlt-1, PlGF, and VEGF) in the development and diagnosis of preeclampsia, emphasizing their importance in understanding the condition since the early 2000s.
- It suggests that the sFlt-1/PlGF ratio is a useful tool for assessing preeclampsia risk and effectiveness of treatments in the second and third trimesters, with specific cutoff values indicating diagnosis and prognosis.
- The identification of angiogenic versus non-angiogenic preeclampsia based on the sFlt-1/PlGF ratio may lead to improved clinical management and safety for mothers and fetuses, potentially influencing future medical guidelines